Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
- Biomea Fusion Inc announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.
- The first presentation covered preclinical data from BMF-219 in high-grade B-cell lymphoma and multiple myeloma.
- BMF-219 exhibits multi-fold higher potency and complete growth inhibition in these preclinical models than clinical reversible menin inhibitors, demonstrating its unique antitumor potential in TP53, KRAS, and NRAS mutated cancers.
- The second presentation detailed a Phase 1 study of BMF-219 in patients with relapsed/refractory acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma.
- Doses of BMF-219 will be escalated in single-subject cohorts independently for each indication until one subject experiences a ≥ Grade 2 related adverse event or dose-limiting toxicity (DLT).
- The primary objective is to determine independently for each cohort/indication the optimal biological dose/ recommended Phase 2 dose (RP2D) of BMF-219 oral monotherapy.
- Key secondary objectives include further evaluation of safety and tolerability, antitumor activity based on best overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and time to progression.
- Enrollment in COVALENT-101 commenced in January 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.